within Pharmacolibrary.Drugs.S_SensoryOrgans.S01B_AntiinflammatoryAgents.S01BC02_Oxyphenbutazone;

model Oxyphenbutazone
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.8,
    Cl = 2.7777777777777776e-07,
    adminDuration = 600,
    adminMass = 200 / 1000000,
    adminCount = 1,
    Vd = 0.01,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0005,
    Tlag = 600);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Oxyphenbutazone</td></tr><tr><td>ATC code:</td><td>S01BC02</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>200</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>10</td><td>L</td></tr>
    <tr><td>clearance:</td><td>1</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Oxyphenbutazone is a nonsteroidal anti-inflammatory drug (NSAID) formerly used for its analgesic and anti-inflammatory properties, primarily in the treatment of rheumatoid arthritis, ankylosing spondylitis, and other musculoskeletal conditions. It is a metabolite of phenylbutazone. Due to serious adverse effects including bone marrow suppression and agranulocytosis, oxyphenbutazone has been withdrawn or severely restricted in many countries and is not commonly used today.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for adults assuming typical NSAID PK characteristics. No recent or accessible peer-reviewed publication directly reports detailed PK model for oxyphenbutazone in humans.</p><h4>References</h4><ol><li><p>Chay, S, et al., &amp; Yocum, J (1984). Population distributions of phenylbutazone and oxyphenbutazone after oral and i.v. dosing in horses. <i>Journal of veterinary pharmacology and therapeutics</i> 7(4) 265–276. DOI:<a href=\"https://doi.org/10.1111/j.1365-2885.1984.tb00911.x\">10.1111/j.1365-2885.1984.tb00911.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/6512917/\">https://pubmed.ncbi.nlm.nih.gov/6512917</a></p></li><li><p>Brouwers, JR, &amp; de Smet, PA (1994). Pharmacokinetic-pharmacodynamic drug interactions with nonsteroidal anti-inflammatory drugs. <i>Clinical pharmacokinetics</i> 27(6) 462–485. DOI:<a href=\"https://doi.org/10.2165/00003088-199427060-00005\">10.2165/00003088-199427060-00005</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/7882636/\">https://pubmed.ncbi.nlm.nih.gov/7882636</a></p></li><li><p>Tobin, T, et al., &amp; Lees, P (1986). Phenylbutazone in the horse: a review. <i>Journal of veterinary pharmacology and therapeutics</i> 9(1) 1–25. DOI:<a href=\"https://doi.org/10.1111/j.1365-2885.1986.tb00008.x\">10.1111/j.1365-2885.1986.tb00008.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/3517382/\">https://pubmed.ncbi.nlm.nih.gov/3517382</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.S.S01BC02 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Oxyphenbutazone;
